HALO

Halozyme Therapeutics, Inc.

43.81 USD
-0.01 (-0.02%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Halozyme Therapeutics, Inc. stock is up 13.91% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 20 May’s closed higher than April. In the last 9 Unusual Options Trades, there were 8 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Apr 18:58 17 May, 2024 40.00 CALL 989 63
01 May 16:47 21 Mar, 2025 40.00 CALL 50 137
06 May 15:21 17 May, 2024 40.00 PUT 250 104
07 May 15:15 21 Mar, 2025 40.00 CALL 50 187
08 May 13:59 20 Dec, 2024 35.00 CALL 50 140
16 May 15:26 21 Jun, 2024 45.00 CALL 338 740
16 May 15:27 20 Dec, 2024 50.00 CALL 318 639
16 May 15:53 17 May, 2024 40.00 CALL 985 1277
23 May 16:50 21 Mar, 2025 45.00 CALL 50 590

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

  • JP Morgan
    Wed May 8, 13:57
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 8, 07:28
    buy
    confirm
  • HC Wainwright & Co.
    Tue May 7, 06:10
    buy
    confirm
  • HC Wainwright & Co.
    Tue Apr 30, 06:34
    buy
    confirm